ArticleNeurotoxicology2010
Endocannabinoid signaling in neurotoxicity and neuroprotection.
Article in Neurotoxicology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 42 citations in OpenAlex.
- Cannabis sativa and/or melatonin do not alter brain lipid but alter oxidative mechanisms in female rats.Journal of cannabis research · 2021Article
- The Endocannabinoid System and Invertebrate Neurodevelopment and Regeneration.International journal of molecular sciences · 2021Review
- The neuropsychopharmacology of cannabis: A review of human imaging studies.Pharmacology & therapeutics · 2019Review
- Cognitive Function in Individuals With Psychosis: Moderation by Adolescent Cannabis Use.Schizophrenia bulletin · 2016Article
- Safety and Toxicology of Cannabinoids.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Review
- Cortical thickness and neurocognition in adolescent marijuana and alcohol users following 28 days of monitored abstinence.Journal of studies on alcohol and drugs · 2014Article
- Article
- Comparative effects of parathion and chlorpyrifos on extracellular endocannabinoid levels in rat hippocampus: influence on cholinergic toxicity.Toxicology and applied pharmacology · 2013Article
- Decreased frontal N-acetylaspartate levels in adolescents concurrently using both methamphetamine and marijuana.Behavioural brain research · 2013Article
- Comparative effects of chlorpyrifos in wild type and cannabinoid Cb1 receptor knockout mice.Toxicology and applied pharmacology · 2011Article
- Is lipid signaling through cannabinoid 2 receptors part of a protective system?Progress in lipid research · 2011Review
- Preliminary evidence for white matter metabolite differences in marijuana-dependent young men using 2D J-resolved magnetic resonance spectroscopic imaging at 4 Tesla.Psychiatry research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
The cannabis plant and products produced from it, such as marijuana and hashish, have been used for centuries for their psychoactive properties. The mechanism for how Delta(9)-tetrahydrocannabinol (THC), the active constituent of cannabis, elicits these neurological effects remained elusive until relatively recently, when specific G-protein coupled receptors were discovered that appeared to mediate cellular actions of THC. Shortly after discovery of these specific receptors, endogenous ligands (endocannabinoids) were identified. Since that time, an extensive number of papers have been published on the endocannabinoid signaling system, a widespread neuromodulatory mechanism that influences neurotransmission throughout the nervous system. This paper summarizes presentations given at the 12th International Neurotoxicology Association meeting that described the potential role of endocannabinoids in the expression of neurotoxicity. Dr. Raphael Mechoulam first gave an overview of the discovery of exogenous and endogenous cannabinoids and their potential for neuroprotection in a variety of conditions. Dr. Larry Parsons then described studies suggesting that endocannabinoid signaling may play a selective role in drug reinforcement. Dr. Carey Pope presented information on the role that endocannabinoid signaling may have in the expression of cholinergic toxicity following anticholinesterase exposures. Together, these presentations highlighted the diverse types of neurological insults that may be modulated by endocannabinoids and drugs/toxicants which might influence endocannabinoid signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.